206 results
Page 7 of 11
8-K
EX-99.1
tlu8u44jsulvxj2k4lrb
16 Mar 20
Regulation FD Disclosure
12:00am
8-K
74z7cox sx4ty9f1ta
20 Feb 20
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date
7:32am
8-K
EX-99.1
wpb 9r92s
20 Feb 20
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date
7:32am
8-K
EX-99.1
m5jh3n7d2n
18 Feb 20
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions
7:30am
424B5
ftals
6 Feb 20
Prospectus supplement for primary offering
5:08pm
8-K
EX-4.2
r6pgzbvfm
6 Feb 20
Entry into a Material Definitive Agreement
9:06am
8-K
EX-4.1
di65wd nptpc
6 Feb 20
Entry into a Material Definitive Agreement
9:06am
8-K
EX-1.1
vnvcm96wt al
6 Feb 20
Entry into a Material Definitive Agreement
9:06am
8-K
EX-99.1
t659i
3 Feb 20
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
7:32am
8-K
EX-99.1
r7be5i
13 Jan 20
Regulation FD Disclosure
7:01am
8-K
EX-99.1
pht0d6d8ip7g2vcz0tfh
4 Dec 19
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
7:31am